US 12,380,981 B2
Closed loop control of physiological glucose
Yamei Chen, Carmel, IN (US); Haoda Fu, Carmel, IN (US); Parag Garhyan, Carmel, IN (US); Ahmad Haidar, Montreal (CA); Richard Earl Jones, Jr., Plainfield, IN (US); Christopher Kovalchick, Bedford, MA (US); Marie Kearney Schiller, Wellesley, MA (US); Monica Rixman Swinney, Stoneham, MA (US); and Howard Allan Wolpert, Brookline, MA (US)
Assigned to Ypsomed AG, Burgdorf (CH)
Filed by Ypsomed AG, Burgdorf (CH)
Filed on Jan. 4, 2024, as Appl. No. 18/404,380.
Prior Publication US 2024/0161900 A1, May 16, 2024
Int. Cl. G16H 20/17 (2018.01); A61M 5/172 (2006.01); G16H 50/50 (2018.01)
CPC G16H 20/17 (2018.01) [A61M 5/1723 (2013.01); G16H 50/50 (2018.01)] 12 Claims
OG exemplary drawing
 
1. A system for providing closed-loop control of physiological glucose, comprising:
a drug delivery device configured to receive a first drug reservoir containing insulin and a second drug reservoir containing glucagon;
a user interface configured to receive user input comprising exercise data;
a glucose measuring device configured to measure a current interstitial glucose; and
a controller,
wherein in response to receipt of the exercise data, the controller is configured to estimate a physiological glucose based on the measured current interstitial glucose, calculate a corrected physiological glucose by subtracting an exercise factor from the estimated physiological glucose, and based on the calculation, to cause a glucagon bolus and an insulin bolus to be delivered in a closed-loop,
wherein the glucagon bolus is deliverable only when a rate of change of the physiological glucose is less than a glucose rate threshold, and
wherein the glucose rate threshold is a function of the estimated physiological glucose.